Olema Pharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
Olema Pharmaceuticals, Inc. carries a market capitalization of 660.61M, placing it among publicly traded companies globally. Its enterprise value stands at 636.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 660.61M |
| Enterprise Value | 636.62M |
Share Statistics
Olema Pharmaceuticals, Inc. currently has 87.45M shares outstanding.
| Shares Outstanding | 87.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 2.54 |
| P/TBV Ratio | 2.54 |
| P/FCF Ratio | -7.42 |
| P/OCF Ratio | -7.42 |
Financial Position
Olema Pharmaceuticals, Inc. maintains a current ratio of 8.86, meaning it holds 8.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.86 |
| Quick Ratio | 8.76 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -52.74 |
| Return on Assets (ROA) | -47.10 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Olema Pharmaceuticals, Inc.'s stock has declined approximately -2.8314% over the past 52 weeks. The 50-day moving average sits at 9.53, while the 200-day moving average is 14.92.
| Beta (5Y) | N/A |
| 52-Week Price Change | -2.8314% |
| 50-Day Moving Average | 9.53 |
| 200-Day Moving Average | 14.92 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -220.67M, while operating income came in at -221.13M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -221.13M |
| Pretax Income | -204.57M |
| Net Income | -204.57M |
| EBITDA | -220.67M |
| EBIT | -221.13M |
| Earnings Per Share (EPS) | -2.09 |
Balance Sheet
Olema Pharmaceuticals, Inc. holds 461.07M in cash and equivalents against 3.66M in total debt, resulting in a net debt position of -45.60M. Total book value stands at 430.56M, with working capital of 416.86M providing operational flexibility.
| Cash & Cash Equivalents | 461.07M |
| Total Debt | 3.66M |
| Net Debt | -45.60M |
| Equity (Book Value) | 430.56M |
| Book Value Per Share | 4.92 |
| Working Capital | 416.86M |
Cash Flow
Olema Pharmaceuticals, Inc. produced -164.74M in operating cash flow over the past twelve months.
| Operating Cash Flow | -164.74M |
| Capital Expenditures | N/A |
| Free Cash Flow | -164.74M |
| FCF Per Share | -1.69 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -23.80 |
| FCF Yield | -13.48 |
Scores
Olema Pharmaceuticals, Inc. posts an Altman Z-Score of 9.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 9.19 |